Craigavon, United Kingdom

Graham Peter Trevitt

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 7.9

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Graham Peter Trevitt - Innovating Cancer Treatment with AKT Inhibitors

Introduction: Graham Peter Trevitt, a talented inventor from Craigavon, GB, has made significant contributions to the field of cancer treatment with his groundbreaking inventions. With a total of 3 patents to his name, Trevitt's work focuses on developing inhibitors of AKT activity, showcasing his dedication to advancing medical research.

Latest Patents:

1. Inhibitors of AKT activity: Trevitt's invention presents a series of compounds specifically designed as inhibitors of the serine-threonine kinase AKT. These compounds show promise in pharmaceutical compositions for treating cancer, offering new avenues for targeted therapy.

2. AKT inhibitor compounds for treatment of cancer: Another patent by Trevitt highlights compounds that serve as inhibitors of AKT activity, emphasizing their utility in combating various isoforms of the serine/threonine kinase. These compounds, when formulated into pharmaceutical compositions, hold potential for innovative cancer treatment methods.

Career Highlights: Graham Peter Trevitt is affiliated with Almac Discovery Limited, a prominent company known for its contributions to the pharmaceutical industry. Working within this dynamic environment, Trevitt has spearheaded research projects that have led to the development of cutting-edge cancer treatments, showcasing his expertise and commitment to scientific innovation.

Collaborations: In his pursuit of scientific excellence, Trevitt has collaborated closely with esteemed colleagues such as Lixin Zhang and Frank Burkamp. Through these partnerships, he has been able to synergize diverse skill sets and perspectives, fostering a collaborative environment conducive to pioneering research in cancer therapeutics.

Conclusion: Graham Peter Trevitt's inventive spirit and unwavering dedication to combating cancer through innovative AKT inhibitors exemplify his profound impact on the field of medical science. His patents stand as a testament to his ingenuity and commitment to improving patient outcomes, setting a high standard for future advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…